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DETECTION OF THE MUTATED K-RAS BIOMARKER IN 
COLORECTAL CARCINOMA, Benjamin R. Doolittle, Janet 
Emanuel, Jose Costa, Department of Pathology, Yale 
University, School of Medicine, New Haven, CT. 
This study describes an advantageous, effective protocol for 
detecting k-ras mutations in human stool as a prototype screen for 
colorectal carcinoma (CRC), the third most common malignancy in the 
United States. A reliable screening test that detects early lesions 
would contribute to a decrease in mortality. Currently, the only non- 
invasive screen for CRC is the heme-occult test which has a high 
false-positive rate. Previously, several investigators have identified 
genetic biomarkers for CRC in stool DNA. The k-ras oncogene, 
mutated in 46-50% of CRC tumors, serves as one molecular marker 
by which stool samples may be evaluated for early detection of 
adenocarcinomas. 
DNA was isolated from stool samples by a new method we 
specifically designed for extracting high quality DNA using 
tetradecyltrimethylammonium oxalate (Catrimox-14). This protocol 
produces an optimal yield of high purity DNA, suitable for 
genotyping. Detection of the human gene in stool samples was 
enhanced by hybrid selection of the k-ras sequences. Polymerase 
Chain Reaction (PCR) and single-strand conformation polymorphism 
(SSCP analysis). 
Tumor tissue and pre-operative stool samples for eight patients 
were k-ras genotyped and compared; stool samples from two 
asymptomatic, healthy patients were also evaluated in a double blind 
format. In seven of eight samples (87%), the genotype of the stool 
and colon tissue DNA was the same. Both healthy patients showed 
wild-type k-ras. This protocol shows promise for the development of 
an efficient and accurate screen for CRC. 
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Detection of the Mutated K-Ras Biomarker 
in Colorecta! Carcinoma 
Yale Medical School Thesis 
Benjamin R. Doolittle 
Thesis Advisors: Janet Emanuel, Jose Costa 
Introduction: 
Colorectal carcinoma is the third most common human 
malignancy in the United States, accounting for 60,000 deaths each 
year. (1) Currently, the only non-invasive screen to detect colorectal 
cancer is the heme-occult test which has a high false-positive rate 
due to benign bleeding diseases such as hemorrhoids, diverticulitis, 
and interference by dietary peroxidases and catalases. Further, 
colorectal tumors less than 2 centimeters in diameter often do not 
bleed. (2) Among patients with malignancy, the sensitivity of the 
heme-occult test is 50-70%. (2) Currently, data are insufficient to 
indicate if screening for colorectal carcinoma with the heme-occult 
test decreases mortality. (2) 
Colorectal carcinoma is curable in 90% of cases if the tumor is 
localized to the inner lining of the colon. Yet, five year survival 
drops to 10% if distant metastasis is present. Because the single most 
important prognostic indicator of colorectal carcinoma is the extent of 

the tumor at the time of diagnosis, a reliable screening tool that 
detects early lesions shows promise to decrease mortality.(3) 
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Mutant oncogenes and tumor suppressor genes provide specific 
markers from which a screening test may be developed. (1) The 
disorganized, unregulated cell growth of malignant cancer is 
associated with a multi-step series of somatic cell mutations. Three 
to six genetic mutations are necessary before the regulatory 
pathways of cell growth are disrupted and dysplastic growth 
occurs.(4) Thus, a mutation acquired in one generation is passed to 
the cell’s progeny which then accumulate new mutations, until the 
ability to regulate cell growth is disrupted. Most cancers occurs in 
the later years of life because this multi-step process may require 
decades.(4) Malignant cells in a tumor have the same mutations as 
the benign cells with the addition of at least one further mutation.(4) 
In colorectal carcinoma, these sequential mutations have been 
characterized.(4) The mutation of k-ras can cause an intermediate 
adenoma. A later “hit” which inactivates the DCC gene may cause a 
late adenoma. Invasive carcinoma is characterized by the loss of 
p53.(4) 
46-50% of of colorectal adenomas and carcinomas show 
mutations of the k-ras oncogene.(2,6) The k-ras protein is located on 
the cytoplasmic side of the cell membrane and functions as a signal 
transducer which promotes cell growth. In the active state, k-ras can 
bind and cleave GTP. The k-ras protein is inactive when bound to 
GDP. A defective k-ras gene which loses GTP-ase activity becomes 
continuously activated, and promotes unregulated, proliferative cell 
growth. (7) Since k-ras is a signal transducer, only one copy of k-ras 
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need be inappropriately activated for unregulated cell growth to 
occur. (6) 
Human stool provides a non-invasive specimen of the colonic 
epithelium and may be used as the material from which DNA can be 
extracted. Genetic markers can then be amplified, and analyzed for 
mutation. Since colonic renewal is estimated at 1% per hour, with an 
entire colonic turnover each 3-4 days, tumor cells are likely being 
shed into stool. (2) While stool provides a non-invasive specimen of 
the colonic carpet, it is a hostile environment for identifying intact 
genes of human origin. Stool contains an abundance of bacteria, 
undigested food particles, bile, mucous, as well as enzymes that can 
break down nucleic acids.(3) 
Initial reports identifying genetic markers from stool DNA 
show promising results. Sidransky et al (1992) first reported that 
among nine patients with k-ras mutations identified in their colon 
tumor, eight (89%) were positive for the same k-ras mutations in 
their stool samples.(l) Smith-Ravin et al (1995) report that 50% of 
stool samples exhibit k-ras mutations identical to the mutation found 
in tumor cells.(2) Eguchi et al (1996) report that among 11 patients 
with a p53 mutation identified in their tumor sample, 7 (64%) show 
evidence of a p53 mutation in their stool sample.(8) Hasegawa 
(1994) was able to detect the identical k-ras mutation in DNA 
extracted from stool in 15 of 19 patients (79%) with colorectal 
tumors.(9) 
More recent studies analyze colonic washings in conjunction 
with endoscopic evaluation to correlate observed endoscopic findings 
with the detectability and genotype of k-ras mutations. Tobi (1994) 
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surveyed 39 healthy patients who were undergoing endoscopy and 
was able to detect a k-ras mutation in 7 of 39 patients (18%). (10) 
Among the colonic washing of 230 patients, Villa was able to amplify 
the k-ras gene sequence in 103 patients (45%) and found only 45 k- 
ras mutations.(11) 
While Sidransky’s initial study demonstrated that existing 
technology could amplify the k-ras gene and identify the mutation in 
the stool, his study was not blinded. More recent, blinded studies 
show a lower yield. Tobi (1994) and Villa (1996) were able to 
amplify less than half of their samples for k-ras. A protocol which 
consistently recovers DNA from stool and reliably amplifies the 
genetic marker would greatly enhance the development of a 
screening test for colorectal carcinoma. 
This study refines the methodology of genetic analysis in 
human feces and incorporates new technology to more accurately 
and efficiently extract and quantify DNA, amplify the k-ras gene, and 
analyze the gene product for mutation. 
In particular, this study uses Catrimox-14 (CM) (Iowa 
Biotechnology Corp., Iowa, USA) to extract DNA from human stool. 
Catrimox-14 is a cationic surfactant, tetra decyltrimethyl-ammonium 
oxalate, that can lyse cells, inhibit ribonucleases, and precipitate RNA 
and DNA in reverse micelles.(13) Catrimox-14 is shown to remove 
inhibitors of Taq polymerase and reverse transcriptase that are 
present in stool.(15) Macfarlane and Dahle (1993) have successfully 
extracted RNA from cells in culture and whole blood.(16,17) 
Uwatoko et al (1996) report that Catrimox-14 has been shown to 
extract viral DNA from fecal specimens of cat, chicken, cow, dog, and 
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gerbil.(14) The role of Catrimox-14 in extracting human DNA from 
stool is not documented and is evaluated in this study. 
Isolation of the k-ras gene sequences from the stool DNA is 
facilitated using oligonucleotide hybridization and streptavidan- 
coated magnetic bead technology. Because DNA quantitation using 
optical absorption has been shown to vary widely compared to gel 
analysis techniques, DNA quantitation was acheived using both 
traditional optical absorption techniques and microfluorimetry with 
SYBR-Green dye.(12) Accurate quantitation of DNA by fluorescence 
determination allows efficient Polymerase Chain Reaction (PCR) and 
Single-Strand Conformational Polymorphism Analysis (SSCP). 
Statement of Purpose: 
This study shows an improved protocol to consistently and 
efficiently recover DNA from human stool, reliably amplify the 
genetic marker and analyze the marker for mutation. This study 
furthers the development of a mutation based screening test for 
colorectal carcinoma. 
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Materials and Methods: 
Samples: Fresh stool samples from a healthy, asymptomatic subject were 
collected and held 1-3 days at 4 °C before processing. Samples 
weighed between .5-1.5 grams. 
Stool and matched tissue samples were collected from patients 
with colorectal cancer and random patients with no personal or 
family history of colorectal cancer. The stool samples were archived 
by Dr. Robert Dubrow (Yale School of Epidemiology and Public 
Health). For archiving purposes, the stool samples had been 
lyophilized at -70 °C. Dry weight of samples were .12-. 14 grams. 
From this bank of samples, 11 stool samples and 23 colon samples 
were processed in a double-blind fashion. 
Samples of tumor and normal tissue for DNA extraction were 
microdissected from sections of paraffin embedded patient 
tissue.(19) 
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Tabic 2. Protocol for Detection of Mutated K-Ras Biomarkers 
of Colorectal Carcinoma 
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DNA Extraction Procedure: 
Two different protocols were followed for DNA extraction from 
stool, a standard organic extraction protocol and the use of Catrimox- 
14, a cationic surfactant. 
A. Organic Extraction: 
The stool was digested in 3 ml of proteinase K solution (250 
mg/ml in 0.01 M Tris-HCl, pH 8.0, 0.1 M NaCl. 0.001 M Na EDTA, 0.5% 
SDS) overnight at 37 °C and extracted twice with equal volumes of 
phenol and twice with equal volumes of phenol:chloroform:isoamyl 
alcohol (25:24:1). Separation of aqueous and non-aqueous phases 
was facilitated by the presence of Phase-Lock-Gel in the tubes 
(5Prime-3Prime, Boulder, CO, USA). 
Each sample was further purified with a potato flour extraction. 
500 mg of potato flour was added to the aqueous sample, rotated for 
1 hour, and centrifuged at 1,500 x g for 7 minutes. Potato flour 
further purifies DNA samples by binding to bile salts and other 
pigments. (20) 
DNA was precipitated from the aqueous phase by addition of 2 
volumes 100% ETOH and .1 volume 3 M NaOAc (f.c. 70% ETOH, .1M 
NaOAc). The samples were stored at -20 °C overnight to ensure 
adequate precipitation. After recentrifugation, the samples were 
suspended in 1-4 ml of TE (10 mM Tris HC1, 1 rnM EDTA, pH 8.0) and 
analyzed using spectrophotometry, microplate fluorimetry with 
SYBR-I Green dye, and agarose gel analysis. (12) 
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B. Catrimox Extraction (Table 3): 
DNA from several lyophilized and fresh stool aliquots were 
extracted using Catrimox-14 (CM) (Iowa Biotechnology Corp., Iowa, 
USA). 
.12-. 15 mg of lyophilized stool samples were mixed with 2.5 ml 
TE (10 mM Tris, 1 M EDTA, pH 8.0) and agitated until a uniform 
sluice formed. The samples were centrifuged at 2,000 x g for 7 
minutes. The supernatant and the stool pellet were processed 
separately. 3 ml of CM was added to both the supernatant and stool 
pellet. The samples were agitated on a shaker for 2-5 hours until a 
uniform sluice formed from the stool pellet. The samples were 
centrifuged at 1,500 x g for 7 minutes. The supernatant was 
removed from each of the CM pellets and processed separately. 
To the CM pellets and CM supernatants, 2 volumes of ethanol 
were added to dissolve the DNA from the CM pellet. Precipitation 
followed with 1 volume of TE and .1 volume of 3 M NaOAc. The 
samples were stored at -20 °C overnight to ensure DNA precipitation. 
Samples were then centrifuged for 10 minutes at 2,500 x g. 
The DNA pellets were washed twice in 70% ethanol, air dried, and 
resuspended in 1 ml of TE. (Figure 1, 2) 

Table 3: Calrimox Extraction Protocol 
(Cat.= Calrimox, pell.=pellel, sup.=supernalanl) 
page 15 
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DNA Quantitation: 
DNA samples were quantified using both optical absorption (OD 
260/280) and the CytoFluor II Multi-Well Fluorescence Reader 
(PerSeptive Biosystems, Inc., USA).(12) The CytoFluor measures 
emission of 520 nm light from fluorescent SYBR-Green I dye 
complexed with DNA. Samples were quantified by diluting 2 
ul, 5 ul, and 10 ul aliquots of DNA sample into a total volume of 150 
ul of TE with 1/2000 dilution of SYBR-Green I dye in a Dynatech 
Microfluor 96 Black “U” Bottom Plate (Dynatech, Virginia, USA). Each 
dilution was repeated in triplicate. Each well was scanned 10 times 
with a fluorescent excitation wavelength of 485+/-20 nm and 
measured the emission wavelength of light at 530 +/- 30 nm. 
A standard curve using known DNA amounts of placental DNA 
was generated. The average of the triplicate values of each dilution 
was used to calculate total DNA per well and DNA per microliter of 
sample. Data were analyzed using Microsoft Excel spreadsheet 
(version 5.0). 
DNA was also quantified using optical absorption for 
comparison. Each sample was diluted to 1/100 and 1/200. 50 ul of 
each diluted sample was placed in a microcuvette and absorption 
was measured at 260 and 280 nm using a Lambda-2 
Spectrophotometer (Perkin-Elmer Corp., Connecticut, USA). 
Enrichment of K-Ras DNA Sequence from Stool DNA: 
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75 |ig of DNA extracted from the lyophilized stool samples was 
denatured at 98 °C for 8 minutes. The samples enriched for the k- 
ras gene sequence were the CM extracted DNA and the CM 
supernatants of the TE sluice (table 3). 1 picomole of biotinylated 
primers R33 and 13 bx, specific for k-ras, were added to the sample 
(R33 5’-GTATCAAAGAATGGTCCTG-3\ 13bx, 5’- 
GTAGTTGGAGCTGGTGG-3’).(19) Primers and DNA annealed at 55 °C 
for 1 hour. 
25 ul of 2 mg/ml Streptavidin magnetic beads (SAMB) 
suspended in 50 mM Tris pH 8.4 was added to each sample. The mix 
was rotated at room temperature for 2 hours. Streptavidin magnetic 
beads (Dynal M-280 Streptavidin) are uniform superparamagnetic, 
polystyrene beads with streptavidin covalently attached to the bead 
surfaced 18) Streptavidin is a protein with a high affinity for biotin 
and enables separation of DNA hybridized to biotinylated 
oligonucleotides. 
The samples were placed in the Dynal Magnetic Particle 
Concentrator (MPC) to concentrate the beads bound with the 
biotinylated DNA. The supernatant was removed. The magnetic 
beads were washed twice with 1 M STE (10 mM Tris, 1 mM EDTA, 1 
M NaCl). 
The DNA was eluted from the magnetic beads by adding 30 ul 
of ddH20 and heated to 70 °C for 10 minutes. After placing the 
sample in the MPC, the ddH20 was removed. 3 ul of lOx TE was 
added to the ddH20 for storage of DNA. 
Polymerase Chain Reaction: 
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K-ras was amplified from both the original CM treated DNA and 
from the enriched samples of k-ras DNA. A 151 base pair product of 
exon 1 of k-ras was amplified from stool using the primers R53 (5’- 
GACTGAATATAAACTTGTGG-3’) and R32 (5’- 
AATGGTCCTGCACCAGTAAT-3’). (19) 
The DNA from the SAMB enrichment was amplified in two 
consecutive PCR reactions (“booster” PCR) in a 30 ul reaction 
containing .1 uM of each R32 and R53 primer, 100 uM of each dNTP, 
0.16 ul of 5 U/ml Ampli7Tr<7 polymerase (Perkin-Elmer, Corp., Wilton, 
CT, USA) and .16 ul of Taq Start Antibody (TSA) in a buffer 
containing 40 mM KC1, 10 mM Tris HC1 pH 8.4, 0.1% Triton X-100, 
0.01% Gelatin, and 2.5 mM MgC12. 
3 ul of the 33 ul isolated enriched k-ras gene was amplified. 
After a 5 minute denaturing step at 96 °C, 5 cycles of stringent 
amplification was completed at 94 °C/30s, 59°C/45s, 73°C/45s, was 
followed by 20 cycles at 92 °C/30s, 56°C/45s, 73°C/45s. 
From this PCR product, 3 ul was re-amplified in a 30 ul reaction 
subject to a denaturing step at 96 °C, followed by 40 cycles of 
amplification at 92 °C/30s, 56 °C/45s, 73 °C/45s in a Hybaid 
OmniGene (Sun Biosciences, Madison, CT, USA). All PCR reactions 
were run with positive and negative DNA controls. 
Quantitation and size of DNA product was evaluated by 
comparison with a standard 100 base pair ladder, GelMarker 
(Research Genetics, Huntsville, AL, USA). 
Single-Strand Conformational Polymorphism: 
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Single-Strand Conformational Polymorphism (SSCP) is a 
technique where mutations may be easily visualized by denaturing 
the DNA sample and running the sample through a high-voltage 
acrylamide gel. Each strand of denatured PCR product forms a 
unique conformation which can be compared to the known wild-type 
and mutant patterns. Genes with even a point mutation are shown to 
exhibit different conformations. 
Conditions for SSCP that distinguish each k-ras mutation have 
been developed.(19) 20 ng of PCR product was denatured using 3 
volumes of DDS (950 ul formamide, 2 ul 5.0 N NaOH, 25 ul 0.1% 
brom-phenol blue, and 25 ul 0.1% xylene cyanol). The mixture was 
heated to 96 °C for 7-10 minutes, quickly placed on ice and loaded 
immediately into a 15% acrylamide mini gel (37.5:1) polymerized 
with 0.075% ammonium persulfate and 0.05% TEMED. The gel was 
run for 80 minutes at 300 volts. 1.0 x TBE buffer was used for gel 
electrophoresis. The gel was quickly washed with TE pH7.4 and 
stained in the dark with SYBR-Green I stain, diluted 1:10,000 in TE 
pH 7.4 for 15 minutes. Imaging was accomplished using an alpha- 
Innotech IS 1000 digital imager with an SG 3 filter (Figure 5, 6). 
Samples were compared with sequence identified mutant controls. 
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Results 
Extraction and Quantitation: 
Catrimox-14 extraction of DNA is an efficient and viable 
alternative to traditional phenol/chloroform extraction techniques. 
Figure 4 shows that the yield from comparative aliquots of stool are 
much greater with the use of Catrimox-14. The yield from the 
clinical stool samples was 664-1750 micrograms of DNA from .12-. 15 
mg of lyophilzed stool sample. Traditional extraction methods 
yielded 250-700 micrograms of DNA from .5 - .75 mg of fresh stool 
sample.(Figure 4) DNA extracted from the TE/Catrimox pellet was 
the most abundant compared to the stool pellet/Catrimox pellet and 
supernatant samples. (Table 3, Figure 2) 
Table 4 compares the amount of DNA quantitated using the 
CytoFluor Fluorescence Emission reader and the optical absorption 
spectrophotometer for the samples visualized in Figure 1. 
Quantitation using the fluorescence analysis with SYBR dyes shows 
consistent readings among diluted samples and confirm the relative 
amounts of DNA visualized on agarose gel analysis. (Figure 1) 
The optical absorption technique shows wide discrepancy in 
readings. (Table 4) For example, optical absorption of the CM pellet 
#2 showed a DNA concentration of 243 ng/ul with a standard 
deviation of 228 ng/ul. An aliquot of sample #2 extracted with the 
phenol/chloroform method showed a five-fold difference in DNA 
concentration between the 1/100 and 1/200 dilutions with an 
average of 1565 ng/ul and a standard deviation of 1973 ng/ul. This 
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inconsistency may be due, in part, to handling and contaminants 
which affect the absorption at the 260 nm and 280 nm wavelengths. 
Purity of the stool DNA samples were low. OD 260/280 ratios, a 
measurement of DNA purity, were between 0.88 - 2.06. (Table 4) 
Comparison between the fluorimetric analysis and optical 
absorption was consistent in only stool sample #6 Catrimox-14 
supernatant which showed an average DNA concentration 273 ng/ul 
and 278 ng/ul respectively. (Table 4) Inconsistencies between 
fluorimetic analysis and optical absoprtion varied by as much as 10- 
fold. 
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Table 4: DNA Quantitation By CytoFluor Plate Reader 
and Optical Density 
Stool Sample 
Cvtofluor Plate 
Reader 
DNA ng/ul 
+/- std.dv. 
Optical Density 
DNA ng/ul 
+/- std.dv. 
QD 
260/280 
#2 cm pellet 617 +/- 33 243 +/- 228 1.26 
#2 cm supernatant 12 +/- 1.7 113 +/- 3.6 2.06 
#6 cm pellet 182 +/- 20 33 +/- 39 1.50 
#6 cm supernatant 273 +/- 20 278 +/- 46 1 .51 
#2 phenol/choloform 135 +/- 18 1565 +/- 1973 1 .07 
#3 685 +/- 91 390 +/- 0 1.21 
#4 2779* 205 +/- 63 0.88 
#5 616 +/- 183 438 +/- 591 0.95 
#6 359 +/- 9 35 +/- 7 0.90 
legend: “cm” represents DNA quantified from a Catrimox-14. 
“phenol/chloroform” repesents DNA quantified from phenol and 
chloroform extraction. * sample #4 has one cytofluor reading. 
Compare with quantitation by gel electrophoresis, Figure 1. 
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k-Ras Enrichment and Polymerase Chain Reaction: 
Isolation of the k-ras gene sequence with the SAMB, and 
amplification by a PCR boost protocol was successful in 10 of 11 
samples. 
When the stool DNA samples were concentrated 5-fold, but not 
enriched for the k-ras gene sequence with the SAMB, no 
amplification of the k-ras gene sequence occured using the booster 
PCR protocol, (data not shown) In five samples of stool DNA enriched 
for the k-ras gene sequence with SAMB (A, B, C, D, J), the k-ras gene 
sequences was amplified in both the CM pellet and supernatant. In 
three samples (E, F, I), the k-ras gene was amplified from the CM 
pellet only. In two samples of stool DNA enriched for the k-ras gene 
sequence (G, H), k-ras was amplified only in the CM supernatant. 
(Table 5) 
Single-Strand Conformational Polymorphism: 
Among the 11 stool samples, 10 amplified k-ras gene sequence 
well enough to provide enough product (20ng) to be genotyped with 
SSCP. The detected mutations in stool samples were 5wt, 2§at, 
2gat/gac, igat/agt? ltgt^ ancj \ unspecific mutation. (Figure 5, Table 
5) 
Among the colon tissue samples which amplified the k-ras gene 
sequence, 20 provided enough product to be genotyped using SSCP. 
The mutations detected in the colon samples were 6wt, 8§aty/a§t, 
4gtt, 2gat/gac. (Figure 6, Table 5) 
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When the k-ras gene sequences from the stool samples and 
colon samples were compared, 2 wild-type stool samples (B, D) 
correllated with two wild-type colon samples. Sample D came from a 
patient with a 2.2cm invasive carcinoma that did not harbor a k-ras 
mutation. Sample J showed wild-type k-ras and came from an 
asymptomatic subject for which no colon tissue specimen was 
available. Sample I also came from an asymptomatic, healthy patient 
without family history for colorectal carcinoma. This patient’s stool 
showed a wild-type mutation and a low-level GAT/GAC mutation in I 
pellet. No gastrointestinal work-up was available to confirm if the 
patient was disease free. 
Among the 7 stool samples which showed mutations in their k- 
ras gene sequence, 5 were the same as those of their corresponding 
tumor. One stool sample showed a non-specific mutation pattern (E 
pellet) which might have reflected both the GTT and AGT mutation 
pattern detected in the colon samples. In the 7th sample (I), a 
mutation was detected in the stool for which there was no colon 
tissue sample to correlate. 
The sensitivity of detecting the same genotype in the stool as in 
the colon sample is (7/8) 87%. To screen for any k-ras sequence 
mutation in the stool for which there is a mutation in the colon, the 
sensitivity is (6/6) 100%. The specificity of detecting a wild-type 
genotype is 100%. However, only two stool samples were tested for 
which a corresponding wild-type sample was obtained. From two 
asymptomatic patients (I, J) for which no colon samples were 
available, both showed wild-type k-ras with a low-level GAT/GAC 
mutation in I pellet.(Table 5) 
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Table 5: Genotype of Stool and Corresponding Tissue DNA 
Stool Sample Mutation Colon Sample Mutation Comments 
A pellet GAT/wt A site 1 wild-type polyp 
A supernatant wild-type A site 2 wild-type polyp 
A site 3 GAT/AGT 2x2 rt transverse 
B pellet wild-type B site 1 wild-type 2.2 cm invasive 
B supernatant wild-type B site 2 wild-type carcinoma 
C pellet GAT C site 1 GAT 3.5x7.5x9 cm 
C supernatant TGT C site 2 GAT rectal carcinoma 
D pellet wild-type D site 1 no amplification 1 x .2 cm margin 
D supernatant wild-type D site 2 wild-type sigmoid colon 
E pellet GTT/unspecified E site 1 GTT lx.5x.5 cm 
mutation E site 2 no amplification sigmoid 
E supernatant no amplification E site 3 ACT appendix 
E site 4 GTT sigmoid 
E site 5 GTT polyp 
F pellet GAT/AGT F site 1 GAT mucosa 
F supernatant no amplification F site 2 GTT 5x5xlcm sigmoid 
G pellet no amplification G site 1 AGT 2.5x2.5x.6cm 
G supernatant GAC G site 2 no amplification sigmoid 
G site 3 AGT 
G site 4 AGT 
H pellet no amplification H site 1 GAT/GAC metastasis 
H supernatnat GAT/GAC H site 2 wild-type primary tumor 
H site 3 GAT/GAC metastasis 
I pellet GAT/GAC/wt asymptomatic 
I supernatant no amplification healthy patient no sample available 
J pellet wild-type asymptomatic 
J supernatant wild-type healthy patient no sample available 
note: Capital letters note the stool sample. Numbers note the colon sample. Thus, “A site 
1” matches both the colon biopsy sample and the corresponding stool sample. 
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Discussion: 
This study describes an accurate, efficient protocol for 
detecting genetic mutations in human stool. While the sample size is 
small, identifying the mutation in the stool had a high sensitivity and 
specificity for predicting the same genotype as in the tumor. This 
study suggests that a screening protocol for colon cancer is possible 
using efficient DNA extraction and isolation techniques and should be 
explored with a larger study sample incorporating a more 
representative population. The use of colonic washings of patients 
undergoing colonoscopy as in the studies of Tobi (1994) and Villa 
(1996) would provide a broad sampling of wild-type and mutants. 
In particular, the use of Catrimox-14 has greatly reduced the 
time involved to extract DNA from human stool. Using the Catrimox- 
14 extraction protocol, the total time for the extraction of the stool 
samples was four hours. Extracting DNA from stool using traditional 
phenol/chloroform extraction methods required at least 3 days to 
allow for adequate digestion with proteinase K, the multiple 
phenol/chloroform/potato flour extractions, and overnight 
precipitation of DNA. The ease and yield of using Catrimox-14 to 
extract DNA from stool shows promise towards developing an 
inexpensive screening test. 
DNA Quantitation Using 
Microfluorimetry and Spectrophotometry 
Microfluorimetry with SYBR-Green dyes quicky and efficiently 
quantitates DNA extracted from stool. The amounts are consistent 
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with that seen on gel analysis. (Figure 1, Table 4) Impurities in the 
stool DNA do not affect the excitation and emission of the SYBR-Green 
dye in the Cytofluorimeter as they do in the optical density 
technique, since fluorescence of dye increases 1000-fold when bound 
to DNA and background fluorescence is very low.(12) Thus, SYBR 
dye fluoresence quantitation permits rapid evaluation of less pure 
samples. The lower limit of the microfluorimetry assay is 100 
picograms.(12) This ability to measure a lower threshold of DNA is 
important when quantifying small amounts of DNA obtained from 
stool or other minimal patient samples. 
The practical lower limit of spectrophotometry is 50-100ng of 
DNA in a 50-100 ul cuvette. (19) Purity of the stool DNA samples 
extracted with Catrimox-14 was poor with A260/280 ratios between 
1.1-1.8. Given the impurities which remain in the DNA samples, 
absorption of light by other materials such as proteins distort the 
accurate quantitation of DNA. 
The SYBR dye fluorescence detection is also an easier, more 
accuarate method than optical absorption for detecting small samples 
of DNA. The samples can be processed simultaneously, with only 1 ul 
of sample required. The optical absorption method requires that 
samples are processed sequentially and results between samples are 
shown to be inconsistent. (Table 4) Fluorescence analysis proves to 
be consistent at several dilutions. Also, several samples can be 
processed simultaneously since they are loaded on a plate with 96 
wells. 
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Character of DNA Extracted from Stool with Catrimox-14 
The k-ras gene sequence was amplified in both Catrimox-14 
pellets and supernatants. This provides a clue to the behavior of 
Catrimox-14 as well as the nature of DNA being shed in stool. The 
DNA present in the supernatant was a very low amount detectable 
only by the CytoFluor Fluorescence reader (data now shown). 
Further, due to the low amount of DNA, only 25 pg was used in the 
isolation technique by the SAMB, while 75 pg of DNA was used from 
the Catrimox-14 pellet. Although only one-third the amount of DNA 
was used for the SAMB isolation, 7 of 10 CM supernatant samples 
were able to amplify their k-ras gene sequence. The “boost” PCR 
protocol was used since 9 % (3 ul of 33 ul) of the DNA eluted from 
the magnetic beads was used in the PCR reaction. An actual 
diagnostic assay could use all of the eluted DNA in a more 
concentrated solution. Since the entire colon sloughs cells into stool, 
then most human DNA in stool would be from non-tumor cells. Yet, 
this study shows that mutated biomarkers in stool which correlate 
with tumor tissue are present in detectable amounts. Tumor tissue 
may be shedding cells at a rate higher than normal tissue. 
Human DNA present in stool may come from cells lysed by the 
Catrimox-14 or from necrosed cells sloughed from tumor. Much of 
the nucleic acids in stool derive from both bacterial RNA and DNA. 
Only 4-10% of DNA in stool is estimated to be human (unpublished 
data, C. Damico, J Emanuel). DNA present in the supernatant may be 
human DNA that was sloughed off from necrosed tumor cells rather 
from intact, normal cells. Since Catrimox-14 is a cationic surfactant 
that lyses cells, perhaps Catrmox has a preference for nucleic acids 
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within the cell rather than free DNA that is derived from necrosed 
tissue. DNA present in the CM supernatant may also be due to 
insufficient amount of Catrimox-14 used. The 3 ml of Catrimox used 
for the .12 - .15 mg lyophilized stool samples might not provide 
enough binding capacity on the reverse micelles to acquire the total 
amount of DNA in the stool samples. 
In addition to lysing cells and forming reverse micelles with 
nucleic acids, Catrimox-14 is shown to remove inhibitors to PCR.(15) 
The removal of inhibitors may facilitate amplification of even the 
slightest amount of DNA. Prior studies used Catrimox-14 to isolate 
viral DNA and RNA from stool with success.(16, 17) Our protocol 
demonstrates excellent yield of DNA from human stool from which 
isolation for the k-ras gene sequence is feasible. 
Further Evaluation is Necessary to Develop Screening Test 
Further experiments on the role of Catrimox-14 in extracting 
DNA from stool remain to be explored before a screening test can be 
incorporated into the regimen of patient care. First, the stability of 
the stool-Catrimox-14 sample must be tested over time. If a patient 
sample is collected in an out-patient setting, the DNA must remain 
intact during the transportation to the lab and the lag time before 
processing. The DNA extracted from the lyophilized clinical samples 
yielded ample DNA. Would the DNA remain stable if it were not 
frozen? Would the most efficacious protocol call for the stool to be 
placed in the Catrimox-14 in the out-patient setting? Does the 
detergent quality of the Catrimox-14 degrade the DNA over time? To 
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apply this technology as a screening test, such practical concerns 
must be resolved. 
Second, the use of hybrid enrichment probes should be further 
explored to incorporate multiple biomarkers for colorectal carcinoma. 
This study shows that oligonucleotide probes are an effective method 
for isolating k-ras as a biomarker in stool DNA. Since a large amount 
of DNA in stool is bacterial, and the number of mutated genes is 
small, efficient enrichment of the DNA sample for the specific 
biomarker is essential to enable PCR amplification. Further, 
incorporating other biomarkers would increase the catchment of the 
screening test. K-ras is mutated in only 46-50% of tumors. Thus, 
between 50-54% of tumors will not be detected since they will have 
wild-type k-ras. Among 230 patients, Villa (1996) amplified the k- 
ras sequence in only 103 patients’ colonic washings and found only 
45 mutations. In this study, sample B had a wild-type k-ras but the 
colon sample showed a 2.2 cm invasive carcinoma. 
The tumor suppressor gene p53 is mutated in 60-86% of 
tumors. Isolating the p53 exons known to be commonly mutated 
(exons 5-8), in addition to the k-ras gene and other biomarkers, 
would augment the ability to identify early lesions. The use of 
hybrid enrichment for multiple biomarkers would broaden the scope 
of the screening test. Given the low and variable levels of human 
DNA in stool, enrichment for the biomarker gene sequence is 
essential for amplification by PCR. Our success with enrichment of 
the k-ras gene sequence with hybrid probes suggest that enrichment 
for multiple biomarkers is feasible. 
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Third, important to the screening test is the size of the tumor 
and its location in the colon. The smallest tumor detected in this 
study was a 1.5 x .5 cm tumor in the sigmoid colon. The smallest 
tumor in the literature cited for this paper is a .5 x .6 cm tumor in 
the rectum by Hasegawa (9) . The most proximal tumor detected in 
this study was 2.5 x 3.0 cm in the ascending colon. The most 
proximal tumor detected in the literature was in the cecum by both 
Sidransky (6x4 cm) and Smith-Ravin (7x7 cm).(l, 2) Since this 
screening test detects the DNA from shed cells, the tumor must be 
large enought to shed sufficient DNA to be detected. Given that 
tumors which have only invaded the mucosa have a 90% recovery, 
the tumor must be detected in its earliest stage for this screening 
test to be effective.(3) The tumor must be large enough to be 
detected, yet small enough to provide a good prognostic indicator for 
survival. The lower-limit of tumor size and its position in the colon 
remains to be evaluated. 
Potential Role of Screening Test in Patient Care 
The role of a screening test for colorectal carcinoma may be 
easily incorporated into the regimen of patient care in the same way 
that Papanicalou smears and mammography are incorporated into 
patient care. The expense and invasiveness of endoscopy are 
impediments towards its use. Further, endoscopy is not readily 
available in all parts of the country. Screening for biomarkers is not 
designed to replace the endoscopic work-up. Rather, screening for 
mutated biomarkers complements the role of physical exam and the 
more definitive endoscopic study. Screening for mutated biomarkers 
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helps raise the suspicion of disease in asymptomatic patients and 
provides a clue towards further work-up. 
In an asymptomatic patient with a family history of colorectal 
carcinoma, for example, the genotype of biomarkers could be 
followed over the course of several years, beginning at an age prior 
to endoscopic work-up. Multiple wild-type biomarkers, such as both 
k-ras and p53, suggest that the patient is disease free. Discovering a 
subsequent mutated biomarker in the asymptomatic patient could 
allow intervention prior to the spread of invasive disease. 
This study demonstrates that the technology exists for 
developing an efficient, viable screen for the third most common 
malignancy in the United States. This study outlines a previously 
unpublished protocol to efficiently extract DNA from human stool 
with a high yield. Further, this study incorporates new technology to 
accurately purify the DNA sample for a biomarker that is capable of 
PCR amplification. The genotype discovered in the stool with SSCP 
correlates with the genotype of the colon samples in 7 of 8 (87%) 
cases with 100% senstivity as a general screen for any k-ras 
mutation. These data are encouraging and strongly suggest that a 
screening test for colorectal carcinoma is accurate and feasible. Using 
this technology, a larger and more representative study population 
would evaluate the role biomarkers play in providing a powerful tool 
towards detection of colorectal carcinoma. 
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Figure 1. Comparison of DNA yield from stool aliquots. Lanes 7-10 
are stool extracted with Catrimox-14. Lanes 11-16 are stool samples 
extracted with the traditional phenol/chloroform/potato flour 
method. The Catrimox-14 extracted samples are from an earlier 
protocol. Compare amounts of DNA by gel analysis with amounts 
measured with Cytofluor Plate Reader and Optical Density (Table 4). 
Lane_Sample 
1 Hind III marker - 500 ng 
2 “ - 250 ng 
3 “ - 100 ng 
4 - 50 ng 
5 - 20 ng 
6 “ - 10 ng 
7 #2 Catrimox-14 pellet DNA extraction 
8 #2 Supernatant from Catrimox-14 pellet 
9 #6 Catrimox-14 pellet DNA extraction 
1 0 #6 Supernatant from Catrimox-14 pellet 
1 1 #2 Phenol/Chloroform/Potato Flour Extracted 
1 2 # 3 
1 3 #4 
1 4 #5 
1 5 # 6 
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Figure 2. Catrimox-14 extraction of DNA from two aliquots of stool 
showing DNA yield from the stool/Catrimox-14 pellet, the 
stool/Catrimox-14 supernatant, the TE/Catrimox-14 pellet, and the 
TE/Catrimox-14 supernatant. Sample is from healthy male. 
Lane Sampie 
EcoRI digested placenta DNA - 
Stool/Catrimox-14 
Stool/Catrimox-14 
Stool/Catrimox-14 
10 Stool/Catrimox-14 
1 1 TE/Catrimox-14 
1 2 TE/Catrimox-14 
pellet #1 
pellet #2 
supernatant 
supernatant 
pellet #1 
pellet #2 
300 ng 
200 ng 
100 ng 
50 ng 
20 ng 
10 ng 
#1 
#2 
1 3 TE/Catrimox-14 
14 TE/Catrimox-14 
supernatant #1 
supernatant #2 
\ 
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200 100 50 20 Fp^ Fs Gp Gs Hp Hs Ip Is Kp Ks 
- 
i I M 
Figure 3. Catrimox-14 DNA Extraction of Clinical Stool Samples. The 
marker lanes of placental DNA are labelled in nanograms. The stool 
samples are labelled with “p” = Catrimox-14 pellet and “s” = 
Catrimox-14 supernatant. 
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* M 
Figure 4. Comparison of DNA extracted with Catrimox-14 and 
Organic protocols. Lambda Hind 111 marker is labelled in nanograms. 
Samples 31 and 71 are clinical stool samples extracted with 
Catrimox-14. “phe” is phenol/chloroform extracted stool DNA. 
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Figure 5. Single-Strand Conformational Polymorphism of K-ras 
Gene Sequence of Stool DNA. Each lane is marked with the 
corresponding stool sample. The “p” is the Catrimox-14 Pellet. The 
“s” is the Catrimox-14 supernatant. 
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Figure 6. Single-Strand Conformational Polymorphism of K-ras 
Gene Sequence of colon DNA samples. Each lane is marked with the 
corresponding colon sample. “HI” corresponds to colon sample H - 
site 1. 
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